FDA panel advises against large opioid-constipation drug safety trials

An advisory committee to the U.S. Food and Drug Administration recommended on Thursday that the agency not require large cardiovascular safety trials for a class of drugs used to treat opioid-induced chronic constipation. Seven panelists voted in favor of such trials for all drugs, five voted in favor of trials for select products and 12 voted against the need for trials. The drugs, known as peripherally acting mu opioid receptor antagonists, include Salix Pharmaceuticals Ltd’s Relistor, also known as methylnaltrexone, and Cubist Pharmaceuticals Inc’s Entereg, also known as alvimopan. AstraZeneca Plc and Nektar Therapeutics also have a product, naloxegol, in development.
Medications/Drugs News Headlines – Yahoo! News

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us